GRI — GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 3
- Website: https://www.gribio.com
Latest SEC filings for GRI
- ARS — 2026-09-28
- 10-Q — 2026-08-14
- SCHEDULE 13G/A — 2026-08-13
- 10-K — 2026-08-07
- NT 10-K — 2026-07-29
- SCHEDULE 13G/A — 2026-05-13
- 10-Q — 2026-03-17
- 10-Q — 2025-12-15
- 10-Q — 2025-09-12
- 10-K/A — 2025-08-22
Latest GRI news
- — GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit (globenewswire.com)
Educational tool only — not investment advice.